What is HC Wainwright’s Estimate for COAG FY2026 Earnings?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) – Equities researchers at HC Wainwright lowered their FY2026 EPS estimates for Hemab Therapeutics in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($3.19) per share for the year, down from their prior estimate of ($3.12). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Hemab Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Hemab Therapeutics’ Q4 2026 earnings at ($0.57) EPS, FY2028 earnings at ($3.62) EPS, FY2029 earnings at ($3.60) EPS and FY2030 earnings at ($2.04) EPS.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17).

Several other equities research analysts have also issued reports on the company. Evercore began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Jefferies Financial Group raised their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price for the company. Finally, Wedbush boosted their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Hemab Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Hemab Therapeutics Stock Performance

Shares of COAG stock opened at $53.48 on Thursday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $54.66. The business has a 50-day moving average price of $38.01. The firm has a market cap of $2.50 billion and a price-to-earnings ratio of -2.23.

Insider Buying and Selling at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of Hemab Therapeutics stock in a transaction on Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 72,467 shares of company stock valued at $1,809,595 over the last ninety days.

Key Hemab Therapeutics News

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target from $52 to $60 and maintained a Buy rating. The new target implies additional upside from the stock’s recent $53.48 level, reinforcing investor optimism about Hemab’s development pipeline and long-term prospects. HC Wainwright Forecasts Strong Price Appreciation for Hemab Therapeutics
• Positive Sentiment: The analyst modestly improved several future earnings forecasts. HC Wainwright raised its estimates for fourth-quarter 2026 EPS to $(0.57) from $(0.60), FY2028 EPS to $(3.62) from $(3.63), FY2029 EPS to $(3.60) from $(3.89), and FY2030 EPS to $(2.04) from $(2.44). These revisions suggest expectations for smaller losses in several out-years.
• Neutral Sentiment: Hemab reported second-quarter 2026 financial results and provided a corporate update. The release gives investors a current update on the company’s financial position and operations, but the supplied report does not include specific revenue, cash-balance, or clinical-development details. Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $(3.19) from $(3.12). The downgrade highlights continued near-term cash-burn and loss risk. Hemab also recently reported quarterly EPS of $(0.80), missing the $(0.63) consensus estimate, while the broader consensus expects a $(2.89) loss for the current year.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.